Data now supports the use of dolutegravir at all stages of pregnancy with no significant increase in neural tube defects. Safety and pharmacokinetic data on newer antiretroviral medications in pregnancy continue to lag behind the general population. While there are multiple safety and tolerability concerns with older regimens, there are now multiple options of regimens that are highly efficacious and have good safety data in pregnancy. Most pregnant patients who are virally suppressed on a well-tolerated regimen are able to safely continue those medications during pregnancy.
结果:数据现在支持在怀孕的所有阶段使用dolutegravir,而神经管缺陷没有显着增加。怀孕期间新型抗逆转录病毒药物的安全性和药代动力学数据继续落后于普通人群。虽然旧方案存在多种安全性和耐受性问题,现在有多种方案可供选择,这些方案非常有效,并且在怀孕期间具有良好的安全性数据.大多数在耐受性良好的方案下受到病毒抑制的怀孕患者能够在怀孕期间安全地继续这些药物。